-- RBグローバル(RBA.TO)は、月曜日に発表した第1四半期の調整後利益と売上高が市場予想を上回ったことを受け、ニューヨーク時間外取引で2%上昇した。 ほとんどの一時的な項目を除いた調整後純利益は、前年同期の1億6520万ドル(1株当たり0.89ドル)から17%増加し、1億8940万ドル(1株当たり1.01ドル)となった。ファクトセットが調査したアナリストのコンセンサス予想は1株当たり1.00ドルだった。 売上高は前年同期比11%増の12億3000万ドルとなり、前年同期の11億1000万ドルを上回り、ファクトセットのアナリスト予想である11億6000万ドルを上回った。サービス売上高は7890万ドルで横ばいだった一方、在庫販売売上高は32%増の3億3690万ドルとなった、と同社は声明で述べた。 RBグローバルは、2026年の総取引額(GTV)成長率を、従来の5~8%から6~9%に上方修正しました。調整後EBITDAは、従来の14億7,000万~15億3,000万米ドルから14億9,000万~15億5,000万米ドルへと予測しています。 ジム・ケスラー最高経営責任者(CEO)は、「当社は全事業分野で幅広いGTV成長を達成しました。これは、当社の成長戦略の強さ、従業員の献身的な努力、そして信頼できるパートナーとしてお客様に提供する価値を改めて示すものです。当社は、特にこの流動的なマクロ経済環境において、自社でコントロールできることに注力し、常に約束以上の成果を上げていくことに努めてまいります」と述べています。 RBグローバルの株価は、時間外取引で0.13米ドル高の105.01米ドルで取引を終えました。トロント証券取引所では、0.37カナダドル高の143.09カナダドルで引けました。
Related Articles
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.